With the rapid development of nanomedicine, nanomaterials (NMs) have been used in clinical medicine to improve treatment efficiency. Bismuth-based nanomaterials(BNMs) are promising candidates for cancer diagnosis and therapy because of their good biocompatibility, low cost, high X-ray attenuation and near infrared absorption coefficient. The traditional therapy mode is relatively single, and the treatment effect is not significantly improved. Therefore, the combination of traditional treatment and emerging treatment not only has high lethality to tumor cell, but also makes up for their shortcomings. This review summarizes the latest research on BNMs in tumor therapy in recent years, including: the design and preparation of BNMs, the synergy of multiple treatment technologies, and the biosafety of nanomaterials. In the end, the inspiration and reference for the study of Bi-based multifunctional nano-platforms were provided for clinical use.
Conventional vaccine adjuvants are limited by their mechanisms of action and administration routes, often failing to simultaneously elicit robust systemic and mucosal immune responses. This limitation compromises the establishment of dual protective barriers during early pathogen invasion. Therefore, we developed an innovative poly (lactic-co-glycolic acid) (PLGA) nanoparticle-based adjuvant system (Res/RA QCS NPs) featuring quaternized chitosan (QCS) surface modification for ovalbumin (OVA) delivery, co-encapsulating dual immunomodulators - resveratrol (Res) and all-trans retinoic acid (RA). The results showed that the Res/RA QCS NPs possessed excellent antigen adsorption capacity (adsorption rate of 93.87 ± 5.27 %) and significantly enhanced the recruitment of antigen-presenting cells (APCs) at the injection site and lymph node-targeting delivery. In vitro immunological evaluation further confirmed that OVA-Res/RA QCS NPs possessed excellent immune-enhancing properties, including: efficient antigen internalization, Dendritic Cells (DCs) maturation activation, enhanced cytokine secretion and mucosal homing ability. In vivo immunity experiments, OVA-Res/RA QCS NPs not only induced high levels of serum antigen-specific IgG antibodies and proliferation and activation of T cells in peripheral lymphoid tissues, but also stimulated the secretion of large amounts of antigen-specific IgA in the gastrointestinal mucosa, which realized the dual activation of systemic and mucosal immunity. This study provides an important theoretical and experimental basis for the development of novel vaccine adjuvants and immunotherapy strategies based on intestinal immunomodulation.

